Samsung Biologics has published its formal offer prospectus to acquire PolyPeptide, deepening its push into peptide manufacturing as CDMOs race to expand capacity for GLP-1 and other peptide-based drugs.
Until further notice, Rettig is taking over the duties of Christian Kullmann, who is recovering in the coming weeks from a recent serious, unplanned surgery.
New GMP (Good Manufacturing Practice) facility to meet increasing demand for lipid nanoparticle (LNP) development and clinical drug product manufacturing.
Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President, and a member of the Extended Executive Committee, effective January 1, 2027.
